Treating Myeloproliferation--On Target or Off?

Affiliations

¹ From the Departments of Oncology (M.A.) and Molecular Biology and Genetics (C.W.G.) and the Sidney Kimmel Comprehensive Cancer Center (M.A., C.W.G.), Johns Hopkins University School of Medicine, Baltimore.

Editorial

Mary Armanios et al. N Engl J Med. 2015.

. 2015 Sep 3;373(10):965-6.

doi: 10.1056/NEJMe1508740.

¹ From the Departments of Oncology (M.A.) and Molecular Biology and Genetics (C.W.G.) and the Sidney Kimmel Comprehensive Cancer Center (M.A., C.W.G.), Johns Hopkins University School of Medicine, Baltimore.

No abstract available

Comment in

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
Bjørn ME, Nielsen CH, Hasselbalch HC. Bjørn ME, et al. N Engl J Med. 2015 Dec 24;373(26):2579-80. doi: 10.1056/NEJMc1512663. N Engl J Med. 2015. PMID: 26699178 No abstract available.

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A. Tefferi A, et al. N Engl J Med. 2015 Sep 3;373(10):908-19. doi: 10.1056/NEJMoa1310523. N Engl J Med. 2015. PMID: 26332545 Clinical Trial.
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A, Daskalakis M, Burington B, Stuart M, Snyder DS. Baerlocher GM, et al. N Engl J Med. 2015 Sep 3;373(10):920-8. doi: 10.1056/NEJMoa1503479. N Engl J Med. 2015. PMID: 26332546 Clinical Trial.